Download PDF
psychoneuro 2005; 31(4): 217-221
DOI: 10.1055/s-2005-870085
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Wie lassen sich monoaminerge, antidepressive Therapien verbessern?

How to improve monoaminergic antidepressive treatments?Stephanie Krüger1
  • 1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl-Gustav Carus, Dresden
Further Information

Publication History

Publication Date:
09 May 2005 (online)

   Permissions and Reprints

Zusammenfassung

Monoamin-basierende antidepressive Substanzen, die selektiv auf den Serotonin-/Noradrenalin- und auch auf die Dopamin-Wiederaufnahme wirken, sind hochwirksam. Allerdings gibt es immer noch eine relativ große Anzahl Patienten, die auf diese Substanzen nicht ausreichend ansprechen. Hinzukommt, dass durch die Wirklatenz von mindestens zwei Wochen wertvolle Behandlungszeit verloren geht. Eine Erhöhung der Effektivität selektiv wirksamer Antidepressiva kann durch Augmentationsstrategien erreicht werden. Außerdem gibt es neuere Antidepressiva, die einen dualen Wirkmechanismus aufweisen, und damit sowohl die serotonerge als auch die noradrenerge Transmission erhöhen. Die Überlegenheit eines dualen Wirkprinzips wird durch eine Reihe klinischer Studien belegt. In diesem Beitrag sollen die Lithium-, die Pindolol- und die Schilddrüsenhormonaugmentation antidepressiver Therapien sowie die beiden Antidepressiva mit dualem Wirkmechanismus, Venlafaxin und Duloxetin, vorgestellt werden.

Summary

Monoaminergic antidepressants that selectively target serotonin-, norepinephrine- or dopamin reuptake are highly effective. There is, however, a significant number of patients that does not or only partially respond to these medications. The 2-week latency of onset is an additional limitation of the uselfulness of these drugs. An increased effectiveness of monoaminergic antidepressants can be achieved by implementing augmentation strategies or by using dual-mechanism antidepressants that target the serotonergic and the noradrenergic transmission. The supremacy of a dual antidepressant mechanism over a selective one is supported by a number of recent studies. In this article, lithium- pindolol- and thyroid-hormone augmentation and the dual-mechanism antidepressants venlafaxine and duloxetine are discussed.

Key Words

depression - antidepressants - venlafaxine - duloxetine

Literatur

  • 1 Aronson R. et al. . Trijodthyronine augmentation in the treatment of refractory depression. A meta-analysis.  Arch Gen Psychiatry. 1996;  53 842-848
    CrossrefPubMedGoogle Scholar
  • 2 Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin-reuptake inhibitors.  Arch Gen Psychiatry. 1994;  51 248-251
    PubMedGoogle Scholar
  • 3 Asberg M, Wagner A. Biochemical effects of antidepressant treatment: studies of monoamine metabolites in cerebrospinal fluid and platelet 3H-imipramine binding.  Ciba Found Symp. 1986;  123 57-83
    PubMedGoogle Scholar
  • 4 Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder.  Int J Neuropsychopharmacol. 2004;  8 1-10
    PubMedGoogle Scholar
  • 5 Bauer M. et al. . Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.  Can J Psychiatry. 2003;  48 440-448
    PubMedGoogle Scholar
  • 6 Bauer M. et al. . Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.  Am J Psychiatry. 2000;  157 1429-1435
    CrossrefPubMedGoogle Scholar
  • 7 Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain.  Mol Psychiatry. 2002;  7 140-156
    CrossrefPubMedGoogle Scholar
  • 8 Berk M, du Plessis AD, Birkett M. Open-abel study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake-inhibitor, in patients with DSM-III-R major depressive disorder.  Int Clin Psychopharmacol. 1997;  12 137-140
    PubMedGoogle Scholar
  • 9 Berman RM, Darnell AM, Miller HL. Effects of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial.  Am J Psychiatry. 1997;  154 37-43
    PubMedGoogle Scholar
  • 10 Bschor T. et al. . Lithium augmentation in treatment resistant depression: clinical evidence, serotonergic and endocrine mechanisms.  Pharmacopsychiatry. 2003;  36 230-234
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Bymaster FP. et al. . Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.  Bioorg Med Chem Lett. 2003;  13 4477-4480
    CrossrefPubMedGoogle Scholar
  • 12 Bymaster FP. et al. . Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.  Neuropsychopharmacology. 2001;  25 871-880
    CrossrefPubMedGoogle Scholar
  • 13 Bymaster FP, Hemrick-Leucke SR, Threlkeld PG. Affinity of duloxetine and venlafaxine for 5-HT and norepinephrine transporters.  In: New Program Abstracts of the 154th APA Meeting. 2001;  34 334
    PubMedGoogle Scholar
  • 14 de Montigny C. et al. . Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.  Arch Gen Psychiatry. 1983;  40 1327-1334
    PubMedGoogle Scholar
  • 15 de Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders.  Br J Psychiatry. 1981;  138 252-256
    PubMedGoogle Scholar
  • 16 Delgado PL, Price LH, Charney DS. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.  Arch Gen Psychiatry. 1990;  47 411-418
    PubMedGoogle Scholar
  • 17 Fava M, Davidson KG. Definition and etiology of treatment-resistant depression.  Psychiatr Clin North Am. 1996;  19 179-200
    CrossrefPubMedGoogle Scholar
  • 18 Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.  J Clin Psychiatry. 2001;  62 16-23
    PubMedGoogle Scholar
  • 19 Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine.  Arch Gen Psychiatry. 2000;  57 503-509
    CrossrefPubMedGoogle Scholar
  • 20 Joffe RT. et al. . A placebo-controlled comparison of litihum and trijothyronine augmentation to tricyclic antidepressants in unipolar refractory depression.  Arch Gen Psychiatry. 1993;  50 387-393
    CrossrefPubMedGoogle Scholar
  • 21 Kessler RC, McGonagle KAZS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey.  Arch Gen Psychiatry. 1994;  51 8-19
    PubMedGoogle Scholar
  • 22 Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.  Arch Gen Psychiatry. 2005;  62 190-198
    CrossrefPubMedGoogle Scholar
  • 23 Martinez D, Hwang D, Mawlawi O. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose occupancy study 11CWAY 100635 and positron emission tomography.  Neuropsychopharmacol. 2001;  24 209-229
    PubMedGoogle Scholar
  • 24 Moreno FA, Gelenberg AJ, Bachar K. Pindolol augmentation of treatment-resistant depressed patients.  J Clin Psychiatry. 1997;  58 437-439
    PubMedGoogle Scholar
  • 25 Nemeroff CB. et al. . Duloxetine for the treatment of major depressive disorder.  Psychopharmacol Bull. 2002;  36 106-132
    PubMedGoogle Scholar
  • 26 Olver JS, Cryan JF, Burrows GD. Pindolol augmentation of antidepressants: a review and rationale.  Aust N Z J Psychiatry. 2000;  43 71-79
    PubMedGoogle Scholar
  • 27 Owens MJ, Morgan WN, Plott SJ. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.  J Pharmacol Exp Ther. 1997;  283 205-223
    PubMedGoogle Scholar
  • 28 Perez V, Gilaberte I, Faries D. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.  Lancet. 1997;  349 1594-1597
    CrossrefPubMedGoogle Scholar
  • 29 Phelps NJ, Cates ME. The role of venlafaxine in the treatment of obsessive-compulsive disorder.  Ann Pharmacother. 2005;  39 136-140
    PubMedGoogle Scholar
  • 30 Raskin J. et al. . Duloxetine in the long-term treatment of major depressive disorder.  J Clin Psychiatry. 2003;  64 1237-1244
    CrossrefPubMedGoogle Scholar
  • 31 Salomon RM, Miller HL, Delgado PL. Use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders.  Int Clin Psychopharmacol. 1993;  8 41-46
    PubMedGoogle Scholar
  • 32 Shelton CI. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?.  J Clin Psychiatry. 2004;  65 29-33
    PubMedGoogle Scholar
  • 33 Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.  Br J Psychiatry. 2001;  178 234-241
    CrossrefPubMedGoogle Scholar
  • 34 Thase ME. Effects of venlafaxine on blood-pressure: a metaanalysis of original data from 3744 depressed patients.  J Clin Psychiatry. 1998;  59 502-508
    PubMedGoogle Scholar
  • 35 Whybrow PC, Prange AJ Jr.. A hypothesis of thyroid-catecholamin-receptor interaction.  Arch Gen Psychiatry. 1981;  38 106-113
    PubMedGoogle Scholar
  • 36 Wong DT, Bymaster FP, Mayle DA. LY248686, a new inhibitor of serotonin and norepinephrine reuptake.  Neuropsychopharmacol. 1993;  8 23-33
    PubMedGoogle Scholar

Korrespondenzadresse:

Priv.-Doz. Dr. med. Stephanie Krüger

Klinik und Poliklinik für Psychiatrie und Psychotherapie am Universitätsklinikum Dresden

Fetscherstr. 74

01307 Dresden

Email: stephanie.krueger@uniklinikum-dresden.de

      >